Loading…
BUMETANIDE is a brand name for Bumetanide. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Bumetanide is indicated whenever diuretic therapy is required in the treatment of oedema, e.g. that associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults, adolescents and children aged 12 years and older Usually 1 mg (5 ml) as a single oral dose given morning or early evening. The dosage should be adjusted according to the patient's response. 5 mg bumetanide per day may be sufficient in some elderly patients.
Paediatric population (children under 12 years) Bumetanide Liquid should not be used for children under 12 years of age. Method of administration For oral administration.
Excessively rapid mobilisation of oedema particularly in elderly patients may give rise to sudden changes in cardiovascular pressure flow relationships with circulatory collapse. This should be borne in mind when bumetanide is given in high doses.
Electrolyte disturbances may occur, particularly in those patients taking a low salt diet. Regular checks of serum electrolytes, in particular sodium, potassium, chloride and bicarbonate should be performed, and replacement therapy instituted where indicated.
As with other diuretics, bumetanide may cause an increase in blood uric acid. 5). Patients with chronic renal failure on high doses of bumetanide should remain under constant hospital supervision. Caution is advised when used in patients with hypotension and in patients with porphyria.
Caution should be exercised when used in patients with hepatic impairment as there may be increased risk of encephalopathy. Bumetanide should be used with caution in patients already receiving nephrotoxic or ototoxic drugs. In patients with known hypersensitivity to sulfonamides or thiazides there may be a potential risk of hypersensitivity to bumetanide.
Toxic epidermal necrolysis (TEN) and Stevens Johnson syndrome (SJS), which can be life-threatening or fatal, have been reported in relation to non-antibiotic sulphonamide containing products, including bumetanide. Patients should be advised of the signs and symptoms of SJS and TEN and closely monitored for those.
If signs and symptoms suggestive of these reactions appear, bumetanide should be withdrawn, and an alternative therapy should be considered. If the patient has developed a serious reaction such as SJS or TEN, with the use of bumetanide, treatment with bumetanide must not be restarted in this patient at any time.
Bumetanide found in urine by doping test is cause for disqualification of athletes.
Excipients:
This medicine contains 1375 mg sorbitol in each spoonful (5 ml) which is equivalent to 275 mg/ml. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. This medicine contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reaction (possibly delayed).
This medicine contains less than 1 mmol sodium (23 mg) per spoonful (5 ml), that is to say essentially ‘sodium-free’
1. Although bumetanide can be used to induce diuresis in renal insufficiency, any marked increase in blood urea or the development of oliguria or anuria during treatment of severe progressing renal disease are indications for stopping treatment with bumetanide.
Bumetanide is contra-indicated in hepatic coma and care should be taken in states of severe electrolyte depletion.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.